{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:07Z","timestamp":1753891207804,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Autoimmune blistering diseases comprise a rare group of potentially life-threatening dermatoses. Management of autoimmune disorders poses a challenge in terms of achieving disease control and preventing adverse events. Treatment often requires an individualized approach considering disease severity, age, comorbidities, and infectious risk especially in the context of the ongoing COVID-19 pandemic. Knowledge regarding SARS-CoV-2 infection is still evolving and no specific antiviral therapy is available yet. We report four patients with active disease that required adjustment of treatment during the pandemic to discuss the use of immunosuppressants and immunobiologics, weighing potential risks and benefits of each therapy modality and vaccination status.<\/jats:p>","DOI":"10.3389\/fmed.2021.811562","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T12:39:58Z","timestamp":1649767198000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report"],"prefix":"10.3389","volume":"8","author":[{"given":"Denise","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Giuli","family":"Santi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina Wakisaka","family":"Maruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.jaad.2020.09.030","article-title":"Absence of specific cutaneous manifestations of severe acute respiratory syndrome coronavirus 2 in a reference center in Brazil","volume":"84","author":"Avancini","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.det.2021.05.014","article-title":"How coronavirus disease 2019 changed dermatology practice in 1 year around the world: perspectives from 11 countries","volume":"39","author":"Sun","year":"2021","journal-title":"Dermatol Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e210040","DOI":"10.1590\/1980-549720210040","article-title":"COVID-19 in the state of S\u00e3o Paulo: the evolution of a pandemic","volume":"24","author":"Lorenz","year":"2021","journal-title":"Rev Bras Epidemiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1529-8019.2007.00136.x","article-title":"Mycophenolate mofetil","volume":"20","author":"Zwerner","year":"2007","journal-title":"Dermatol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/vaccines9060596","article-title":"the many faces of innate immunity in SARS-CoV-2 infection","volume":"9","author":"Hanan","year":"2021","journal-title":"Vaccines."},{"key":"B8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/1348-0421.12828","article-title":"Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2","volume":"64","author":"Kato","year":"2020","journal-title":"Microbiol Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaad.2012.07.003","article-title":"Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases","volume":"68","author":"Sokumbi","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2020.08.012","article-title":"COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases","volume":"84","author":"Kasperkiewicz","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1111\/jdv.17207","article-title":"Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/1346-8138.14503","article-title":"Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios","volume":"45","author":"Kridin","year":"2018","journal-title":"J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jaad.2020.12.043","article-title":"Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study","volume":"84","author":"Mahmoudi","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"573044","DOI":"10.3389\/fphys.2020.573044","article-title":"Heparin therapy improving hypoxia in COVID-19 patients - a case series","volume":"11","author":"Negri","year":"2020","journal-title":"Front Physiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jamainternmed.2020.3030","article-title":"Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure","volume":"180","author":"Thompson","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clindermatol.2021.01.007","article-title":"Impact of COVID-19 on autoimmune blistering diseases","volume":"39","author":"Drenovska","year":"2021","journal-title":"Clin Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1684\/ejd.2021.4043","article-title":"Considerations on SARS-CoV-2 vaccines in patients with autoimmune blistering diseases","volume":"31","author":"Cozzani","year":"2021","journal-title":"Eur J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/bjd.20571","article-title":"COVID-19 outcomes in patients with autoimmune blistering disease","volume":"185","author":"Hwang","year":"2021","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1160\/TH15-04-0309","article-title":"Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study","volume":"115","author":"Cugno","year":"2016","journal-title":"Thromb Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3389\/fimmu.2019.01559","article-title":"the risk of pulmonary embolism in patients with pemphigus: a population-based large-scale longitudinal study","volume":"10","author":"Kridin","year":"2019","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e14361","DOI":"10.1111\/dth.14361","article-title":"Immunobullous diseases, prothrombotic state, and COVID-19: role of prophylactic anticoagulation in bullous pemphigoid and pemphigus","volume":"33","author":"Anuragi","year":"2020","journal-title":"Dermatol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","article-title":"Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira","year":"2021","journal-title":"Blood Adv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","article-title":"COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence","volume":"85","author":"Wack","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e649","DOI":"10.1111\/jdv.17480","article-title":"Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2","volume":"35","author":"Solimani","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20890","article-title":"Bullous pemphigoid after SARS-CoV-2 vaccination: spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies","author":"Gambichler","year":"2021","journal-title":"Br J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1111\/jdv.17472","article-title":"The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?","volume":"35","author":"Damiani","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.jaad.2020.09.002","article-title":"Authors' reply to the comment \u201cTreatment considerations for patients with pemphigus during the COVID-19 pandemic\u201d","volume":"84","author":"Shakshouk","year":"2021","journal-title":"J Am Acad Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.811562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T12:40:01Z","timestamp":1649767201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.811562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":30,"alternative-id":["10.3389\/fmed.2021.811562"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.811562","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"article-number":"811562"}}